Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of $0.41, $0.09 better than the analyst estimate of $0.32. Revenue for the quarter came in at $85.4 million versus the consensus estimate of $81.62 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2023 revenue of $195-205 million, versus the consensus of $165.8 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.